RepliCel CEO, David Hall, will present at the 11th Annual BioPartnering North America Conference in Vancouver, BC, on Monday, February 25th at 10:30am in room 121
Vancouver, BC (PRWEB) February 19, 2013
RepliCel Life Sciences Inc (the “Company” or “RepliCel”) (OTCBB: REPCF) (CNSX: RP) today announced that the Company will present to a select group of biotech industry investors and experts at the 11th Annual BioPartnering North America Conference (“BPN”) in Vancouver, BC, on Monday, February 25th at 10:30am in room 121. David Hall, CEO, will give a corporate overview on RepliCel’s autologous cell replication technology and current clinical development plans.
Following the BPN conference, RepliCel is set to attend the 7th World Congress for Hair Research in Edinburgh on May 4-6th 2013. The Company looks forward to another international gathering of the global hair research societies.
About BioPartnering North America
BPN, the only global life science conference in Canada, provides presenters, exhibitors, and attendees with a unique chance to access innovations and technologies from all around the world. By bringing together senior executives from venture capital firms, major pharmaceutical companies, academia, and government representatives, BPN offers networking and information sharing opportunities. RepliCel’s presentation will be made available on the Company’s web site. This year, the 3-day event starts on February 24th.
About RepliCel Life Sciences
The Company has developed RepliCel™, a natural hair cell replication technology that has the potential to become the world’s first, minimally invasive solution for androgenetic alopecia (pattern baldness) and general hair loss in men and women. RepliCel™ is based on autologous cell implantation technology that replicates a patient’s hair cells from their own healthy hair follicles and, when reintroduced into areas of hair loss, the Company hopes to initiate natural hair regeneration. Patents for the technology have been issued by the European Union and Australia and are pending in other major international jurisdictions. The RepliCel™ procedure has been developed over the past ten years by the Company’s recognized research scientists and medical experts – specialists in the fields of hair growth, hair biology and dermatology. Additional information on RepliCel is available at http://www.replicel.com.
Notice Regarding Forward Looking Statements
This press release contains projections and forward-looking statements, as that term is defined under applicable securities laws. Statements in this press release, which are not purely historical, are forward-looking statements that relate to the Company’s expected timeline regarding the timing and objectives of the interim analysis to be completed after the completion of the final patient’s six month follow-up visit, the participation of subjects after completion of such analysis and the timing of the expected commencement of the Company’s Phase IIb clinical trial. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: negative results from the Company’s clinical trials; the effects of government regulation on the Company’s business; risks associated with the Company’s ability to obtain and protect rights to its intellectual property; risks and uncertainties associated with the Company’s ability to raise additional capital; and other factors beyond the Company’s control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made, and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2010 and other periodic reports filed from time-to-time with the Securities and Exchange Commission on Edgar at http://www.sec.gov and with the British Columbia Securities Commission on Sedar at http://www.sedar.com.